Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.2%

2 terminated/withdrawn out of 48 trials

Success Rate

95.5%

+8.9% vs industry average

Late-Stage Pipeline

42%

20 trials in Phase 3/4

Results Transparency

43%

18 of 42 completed trials have results

Key Signals

18 with results

Enrollment Performance

Analytics

Phase 3
13(43.3%)
Phase 4
7(23.3%)
Phase 2
6(20.0%)
Phase 1
4(13.3%)
30Total
Phase 3(13)
Phase 4(7)
Phase 2(6)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials
NCT01139866Completed

An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery

Role: collaborator

NCT00993798Phase 2Completed

An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery

Role: collaborator

NCT00798967Phase 3Completed

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Role: collaborator

NCT00818363Phase 2Completed

A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder Surgery

Role: collaborator

NCT01052012Phase 3Completed

Bupivacaine Effectiveness and Safety in SABER® Trial

Role: collaborator

NCT00993226Phase 2Completed

An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy

Role: collaborator

NCT00974350Phase 2Completed

A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair

Role: collaborator

NCT02549521Phase 1Completed

Mg Induced Changes From Day 0 to Day 28 on Serum and Urine Bone Metabolic Parameters in 70 y Old Females (no 50).

Role: collaborator

NCT00999999Phase 4Completed

Efficacy of Tachosil as Dural Sealant Compared to Standard Treatment

Role: collaborator

NCT00829738Completed

Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease

Role: lead

NCT00830115Completed

Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders

Role: lead

NCT00561730Completed

Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)

Role: lead

NCT00700141Completed

Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®

Role: lead

NCT00699335Completed

Matrifen® for Therapy of Severe Chronic Pain®

Role: lead

NCT00713258Phase 4Terminated

The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)

Role: lead

NCT00440401Phase 4Completed

TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)

Role: lead

NCT00562094Completed

Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)

Role: lead

NCT00479037Phase 4Completed

Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)

Role: lead

NCT00713661Phase 2Completed

Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM)

Role: lead

NCT00290849Completed

ImproveR International (BI-001-IM)

Role: lead